{"disease":{"id":"hypercholesterolemia","name":"hypercholesterolemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":28,"pipeline_drug_count":0,"trial_count":14},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"evolocumab","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"atorvastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inclisiran","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqvio","generic_name":"INCLISIRAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":59,"revenue":"863","mechanism":"Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors."},{"drug_id":"alirocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"alirocumab","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"lomitapide","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Juxtapid","generic_name":"LOMITAPIDE","company_name":"Chiesi","drug_phase":"marketed","molecular_target":"Microsomal triglyceride transfer protein large subunit","drug_class":"Microsomal Triglyceride Transfer Protein Inhibitor","quality_score":60,"revenue":"126","mechanism":"Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream."},{"drug_id":"lerodalcibep","indication_name":"heterozygous familial hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lerochol","generic_name":"LERODALCIBEP","company_name":"Lib Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels."},{"drug_id":"niaspan","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mipomersen","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kynamro","generic_name":"MIPOMERSEN","company_name":"Kastle Theraps Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antisense Oligonucleotide","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"fluvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"fluvastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"colestipol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colestid","generic_name":"Colestipol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetimibe","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"probucol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorelco","generic_name":"PROBUCOL","company_name":"","drug_phase":"marketed","molecular_target":"Serine protease hepsin","drug_class":"probucol","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"livalo","indication_name":"Familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livalo","company_name":"Kowa Research Institute, Inc.","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"livalo","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livalo","company_name":"Kowa Research Institute, Inc.","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"evinacumab-dgnb","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EVKEEZA","generic_name":"EVINACUMAB-DGNB","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cholestyramine","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"myoinositol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"niacin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"niacin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"fenofibrate","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"colesevelam","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welchol","generic_name":"COLESEVELAM","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":10,"revenue":null,"mechanism":"Welchol works by binding to bile acids in the gut, reducing their reabsorption and increasing their excretion, which in turn lowers cholesterol levels and improves blood sugar control."},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"rosuvastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"bempedoic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexletol","generic_name":"BEMPEDOIC ACID","company_name":"Esperion Theraps Inc","drug_phase":"marketed","molecular_target":"ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1)","drug_class":"Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lipitor","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"evinacumab","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evkeeza","generic_name":"EVINACUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood."},{"drug_id":"bezafibrate","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Befizal","generic_name":"BEZAFIBRATE","company_name":"","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"bezafibrate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pitavastatin","indication_name":"Familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livalo","generic_name":"PITAVASTATIN","company_name":"Kowa Co","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"pitavastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livalo","generic_name":"PITAVASTATIN","company_name":"Kowa Co","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cerivastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baycol","generic_name":"CERIVASTATIN","company_name":"Bayer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"cerivastatin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"lovastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"lovastatin","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"cholestyramine","indication_name":"Primary Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"welchol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Welchol","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Heterozygous Familial Hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"caduet","indication_name":"Homozygous Familial Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"inositol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"nicotinic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"nicotinic-acid","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"ezetrol","indication_name":"Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"lerodalcibep","indication_name":"hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lerochol","generic_name":"LERODALCIBEP","company_name":"Lib Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels."}],"pipeline":[],"offLabel":[],"totalMarketed":63,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03989167","title":"Clinical Decision Support for Familial Hypercholesterolemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":460000,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT07023445","title":"Patterns of Inclisiran Use in the Real World: An Analysis of US Databases","phase":"","overall_status":"COMPLETED","enrollment_count":37688,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04402112","title":"Efficacy and Safety of Pitavastatin in a Real-world Setting","phase":"","overall_status":"COMPLETED","enrollment_count":28343,"lead_sponsor_name":"JW Pharmaceutical","has_results":false},{"nct_id":"NCT03394859","title":"Electronic Medical Records and Genomics (eMERGE) Phase III","phase":"","overall_status":"COMPLETED","enrollment_count":25380,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT00202878","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18144,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT04507984","title":"Universal Familial Hypercholesterolemia Screening in Children","phase":"","overall_status":"COMPLETED","enrollment_count":17000,"lead_sponsor_name":"University of Ljubljana, Faculty of Medicine","has_results":false},{"nct_id":"NCT04529967","title":"Child-Parent Familial Hypercholesterolemia Screening","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04118348","title":"Evaluating the Efficacy of Pediatric Lipid Screening Alerts","phase":"NA","overall_status":"COMPLETED","enrollment_count":13340,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT07409636","title":"A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients","phase":"","overall_status":"COMPLETED","enrollment_count":11991,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06362473","title":"Lipid Transport Disorder Italian Genetic Record (LIPIGEN)","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","has_results":false},{"nct_id":"NCT04271280","title":"Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events","phase":"","overall_status":"COMPLETED","enrollment_count":9559,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":true},{"nct_id":"NCT07445542","title":"Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia","phase":"","overall_status":"COMPLETED","enrollment_count":6927,"lead_sponsor_name":"JW Pharmaceutical","has_results":false},{"nct_id":"NCT02808403","title":"Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05218304","title":"Baromètre Santé Adulte 2021-2022","phase":"NA","overall_status":"SUSPENDED","enrollment_count":5471,"lead_sponsor_name":"Agence Sanitaire et Sociale de Nouvelle Calédonie","has_results":false},{"nct_id":"NCT02565615","title":"Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":5115,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT06293261","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","phase":"","overall_status":"COMPLETED","enrollment_count":5047,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT05430828","title":"Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT04579367","title":"Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT07468500","title":"Real World Adherence of PCSK9 Targeted Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03814187","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01414192","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","phase":"","overall_status":"COMPLETED","enrollment_count":3215,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT06287177","title":"Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT06492291","title":"Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05952856","title":"A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2912,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06304415","title":"Elevated Lipoprotein(a) in Hospital Staff","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT05142722","title":"Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2530,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT00479882","title":"MK-0524B Lipid Study (MK-0524B-063)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2414,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02666664","title":"Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2230,"lead_sponsor_name":"Esperion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT02957682","title":"Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2176,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT00353782","title":"Causes and Natural History of Dyslipidemias","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04798430","title":"Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT05614219","title":"Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05271305","title":"Pilot Study for a National Screening for Familial Hypercholesterolemia","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Centre Hospitalier du Luxembourg","has_results":false},{"nct_id":"NCT07524101","title":"Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1952,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05362903","title":"A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1868,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05559606","title":"An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe","phase":"","overall_status":"COMPLETED","enrollment_count":1839,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05192941","title":"Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT07382778","title":"Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":1538,"lead_sponsor_name":"JW Pharmaceutical","has_results":false},{"nct_id":"NCT06770543","title":"Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07374861","title":"Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03067441","title":"Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1462,"lead_sponsor_name":"Esperion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03694197","title":"Long Term Safety Study of PRALUENT","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1389,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT01439880","title":"Open Label Study of Long Term Evaluation Against LDL-C Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1324,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01274559","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1173,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01335997","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1139,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03398954","title":"a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia","phase":"","overall_status":"UNKNOWN","enrollment_count":1128,"lead_sponsor_name":"China Cardiovascular Association","has_results":false},{"nct_id":"NCT03110250","title":"Familial Hypercholesterolemia in Turkey (A-HIT2)","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT03597958","title":"Genetic Causes of Hypercholesterolaemia in the Emirati Population","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Imperial College London Diabetes Centre","has_results":false},{"nct_id":"NCT00092846","title":"A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false}],"total":50},"guidelines":[{"drug_id":"atorvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null},{"drug_id":"atorvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null},{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null},{"drug_id":"lipitor","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null},{"drug_id":"lipitor","guideline_body":"FDA label","recommendation":"As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}